Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

被引:287
作者
van de Donk, Niels W. C. J. [1 ]
Janmaat, Maarten L.
Mutis, Tuna [1 ]
van Bueren, Jeroen J. Lammerts
Ahmadi, Tahamtan [2 ]
Sasser, A. Kate [2 ]
Lokhorst, Henk M. [1 ]
Parren, Paul W. H. I. [3 ,4 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
[2] Janssen Res & Dev, Spring House, PA USA
[3] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense, Denmark
[4] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands
关键词
CD38; therapeutic antibody; daratumumab; isatuximab; multiple myeloma; cancer; CYCLIC ADP-RIBOSE; LENALIDOMIDE PLUS DEXAMETHASONE; AUTOREACTIVE PLASMA-CELLS; HIGH-DOSE DEXAMETHASONE; MULTIPLE-MYELOMA CELLS; RETINOIC ACID; ANTITUMOR-ACTIVITY; BONE-MARROW; INTERGROUPE FRANCOPHONE; THERAPEUTIC ACTIVITY;
D O I
10.1111/imr.12389
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38. The protein is also expressed in a subset of hematological tumors, and shows especially broad and high expression levels in plasma cell tumors such as multiple myeloma (MM). Together, this triggered the development of various therapeutic CD38 antibodies, including daratumumab, isatuximab, and MOR202. Daratumumab binds a unique CD38 epitope and showed strong anti-tumor activity in preclinical models. The antibody engages diverse mechanisms of action, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, programmed cell death, modulation of enzymatic activity, and immunomodulatory activity. CD38-targeting antibodies have a favorable toxicity profile in patients, and early clinical data show a marked activity in MM, while studies in other hematological malignancies are ongoing. Daratumumab has single agent activity and a limited toxicity profile, allowing favorable combination therapies with existing as well as emerging therapies, which are currently evaluated in the clinic. Finally, CD38 antibodies may have a role in the treatment of diseases beyond hematological malignancies, including solid tumors and antibody-mediated autoimmune diseases.
引用
收藏
页码:95 / 112
页数:18
相关论文
共 153 条
[1]   ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP(+) [J].
Aarhus, R ;
Graeff, RM ;
Dickey, DM ;
Walseth, TF ;
Lee, HC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (51) :30327-30333
[2]   Dilemmas in Treating Smoldering Multiple Myeloma [J].
Ahn, Inhye E. ;
Mailankody, Sham ;
Korde, Neha ;
Landgren, Ola .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (01) :115-U178
[3]  
[Anonymous], 2000, HUMAN CD38 RELATED M
[4]  
[Anonymous], BLOOD
[5]  
[Anonymous], ASH ANN M, DOI DOI 10.1182/BL00D-2011-10-384685
[6]  
[Anonymous], 2014, BLOOD
[7]  
[Anonymous], BLOOD
[8]   Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma [J].
Benboubker, Lotfi ;
Dimopoulos, Meletios A. ;
Dispenzieri, Angela ;
Catalano, John ;
Belch, Andrew R. ;
Cavo, Michele ;
Pinto, Antonello ;
Weisel, Katja ;
Ludwig, Heinz ;
Bahlis, Nizar ;
Banos, Anne ;
Tiab, Mourad ;
Delforge, Michel ;
Cavenagh, Jamie ;
Geraldes, Catarina ;
Lee, Je-Jung ;
Chen, Christine ;
Oriol, Albert ;
de la Rubia, Javier ;
Qiu, Lugui ;
White, Darrell J. ;
Binder, Daniel ;
Anderson, Kenneth ;
Fermand, Jean-Paul ;
Moreau, Philippe ;
Attal, Michel ;
Knight, Robert ;
Chen, Guang ;
Van Oostendorp, Jason ;
Jacques, Christian ;
Ervin-Haynes, Annette ;
Avet-Loiseau, Herve ;
Hulin, Cyrille ;
Facon, Thierry .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) :906-917
[9]  
Berthelier V, 2000, EUR J BIOCHEM, V267, P3056, DOI 10.1046/j.1432-1033.2000.01329.x
[10]   Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca2+ influx and induces streamers [J].
Beum, Paul V. ;
Lindorfer, Margaret A. ;
Peek, Elizabeth M. ;
Stukenberg, P. Todd ;
de Weers, Michel ;
Beurskens, Frank J. ;
Parren, Paul W. H. I. ;
van de Winkel, Jan G. J. ;
Taylor, Ronald P. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (08) :2436-2446